Last reviewed · How we verify
NCT07435961
Magnetotherapy in Carpal Tunnel Syndrome: Randomized Controlled Study
NA trial testing Arm 1: Active Magnetotherapy Group in Magnetotherapy in 60 participants. Not yet recruiting.
1 June 2026
Quick facts
| Lead sponsor | Fatih Sultan Mehmet Training and Research Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 February 2026 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 November 2026 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Arm 1: Active Magnetotherapy Group
- Arm 2: Sham (Placebo) Magnetotherapy Group
- Arm 3: Conservative Treatment (Wait-List Control) Group
Conditions studied
- Magnetotherapy — all drugs for Magnetotherapy →
- Carpal Tunnel Syndrome (CTS) — all drugs for Carpal Tunnel Syndrome (CTS) →
- Median Nerve Compression — all drugs for Median Nerve Compression →
Sponsor
Fatih Sultan Mehmet Training and Research Hospital
Who can join
Adults 18 to 65, any sex, with Magnetotherapy or Carpal Tunnel Syndrome (CTS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to investigate the effectiveness of low-frequency pulsed electromagnetic field therapy in individuals diagnosed with mild-to-moderate carpal tunnel syndrome (CTS). This double-blind, randomized controlled trial will randomly assign participants into three groups: Group 1: Active magnetotherapy Group 2: Placebo magnetotherapy (treatment using an identical device that does not generate a magnetic field) Group 3: Routine (conservative) treatment group All participants will receive a standard nighttime wrist splint and a standardized nerve and tendon gliding exercise protocol. Magnetic field applications will be administered five days per week for a total of 15 sessions. Assessments will be conducted at baseline (T0), at the end of treatment (T1 - Week 3), at 1 month (T2), and at 3 months (T3). The primary outcome measures include the Boston Carpal Tunnel Questionnaire (BCTQ), pain intensity assessed by the Visual Analog Scale (VAS), functional status measured by QuickDASH, median nerve cross-sectional area assessed by ultrasonography, sensory function evaluated using the Semmes-Weinstein monofilament test, grip strength measured by dynamometry, and clinical test results (Tinel and Phalen tests). Secondary outcomes include sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI) and patient satisfaction. This study aims to contribute to the scientific evidence regarding the effectiveness of magnetotherapy as a non-invasive treatment option for carpal tunnel syndrome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07435961
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fatih Sultan Mehmet Training and Research Hospital trials
Trials by the same sponsor.
- NCT07589582 — Active Noise-Cancelling Headphones Reduce Operative Time and Improve Procedural Consistency in ACL Reconstruction l · NA · active not recruiting
- NCT07523828 — Laryngeal Edema Assessment by Cuff Leak Test and Ultrasound in ICU Patients and Its Relationship With Weaning Success · not yet recruiting
- NCT07487038 — The Efficacy and Safety of a Single-Dose Hyaluronic Acid Injection in the Treatment of Knee Osteoarthritis · not yet recruiting
- NCT07485465 — Lymphoedema Diagnosis and Treatment · not yet recruiting
- NCT07451925 — Prediction of Postoperative Pain Using Venous Cannulation Pain and Preoperative Anxiety Scores · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07435961 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fatih Sultan Mehmet Training and Research Hospital
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07435961.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing